News

First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex (daratumumab) in people with heavily treated multiple myeloma. The trial, dubbed LIGHTHOUSE (NCT04649060), had been delayed by the COVID-19 pandemic but is now…

PT-112 Shows Promise for Heavily Treated Myeloma Patients

Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory multiple myeloma. The findings were shared in a presentation, “A Phase I Dose Escalation Study of PT-112 in Patients with Relapsed or…

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel  — known as cilta-cel — to treat adults with relapsed or refractory (hard-to-treat) multiple myeloma. A rolling submission of the biologics license application (BLA) for cilta-cel has been started by Janssen…

GSK Seeks Ideas for Improving Life in Myeloma Community

A new initiative by GlaxoSmithKline (GSK) is seeking project proposals that will address key needs for people in the multiple myeloma community. Submissions for the Target the Future Think Tank Challenge are open until Feb. 11. Anyone in the community, including patients, caregivers, researchers, clinicians, and advocates, all…

Bispecific Antibody Shows Early, Promising Responses in Trial

PF-06863135, a bispecific antibody being developed by Pfizer as an injectable treatment, shows a manageable safety profile and promising response rates at high dose in heavily pre-treated patients with relapsed or refractory multiple myeloma, according to early data from an ongoing Phase 1/2 trial. “The very high response…

MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma

The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) — a precursor condition to multiple myeloma. The collaboration will take advantage of MMRF’s data hub CureCloud and at-home genetic test program and Dana Farber’s…